Engflag

Dexibuprofen

Quick links to important sections

Dexibuprofen

Dexibuprofen_FR

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dexibuprofen

What is Dexibuprofen? Definition and Chemical Identity

Property Description
Active ingredient Dexibuprofen ((S)-ibuprofen)
Form Oral preparation (tablet)
Pharmacological class Non-steroidal Anti-inflammatory Drug (NSAID)
General purpose Pain relief, fever reduction, anti-inflammation
Origin Synthetic

Dexibuprofen is a synthetic, single-entity pharmaceutical compound classified as a Non-steroidal Anti-inflammatory Drug (NSAID) used for its core pain-relieving, fever-reducing, and anti-inflammatory properties.

It is the official International Nonproprietary Name (INN) for the isolated, therapeutically active component of Ibuprofen, specifically known as (S)-ibuprofen or S(+)-ibuprofen. Standard Ibuprofen is a racemic mixture containing two mirror-image molecules (enantiomers), only one of which—the S(+) form (Dexibuprofen)—is primarily responsible for the therapeutic effect. Dexibuprofen is therefore a single-enantiomer NSAID, containing exclusively the active stereoisomer. This targeted chemical structure is intended for delivering anti-inflammatory and analgesic actions.

Classifying Dexibuprofen: Type, Form, and General Purpose

Dexibuprofen belongs to the pharmacological class of propionic acid derivatives, which is a subdivision of the broader Non-steroidal Anti-inflammatory Drug (NSAID) group.

The core function of this synthetic drug is the inhibition of the cyclooxygenase (COX) enzymes, which are crucial for the biosynthesis of inflammatory mediators called prostaglandins. Its general purpose is therefore to provide broad, systemic relief by mitigating these inflammatory signals, making it suitable for managing common discomforts, such as the aches and pains associated with a mild, short-term inflammatory condition. Dexibuprofen is designed for oral administration and is typically presented as a tablet or film-coated tablet, making it a standardized oral preparation.

Dexibuprofen as a Single-Enantiomer Medication

The distinction of Dexibuprofen as a single-enantiomer medication reflects a development strategy aimed at utilizing only the specific molecular configuration responsible for the desired pharmacological activity.

This approach utilizes the fact that the S(+) isomer is the entity that directly contributes to the therapeutic effects, while the R(-) isomer of racemic Ibuprofen is considered less potent, though it undergoes partial inversion to the active form. By administering only the S(+) isomer, the drug's activity is concentrated in the most effective chemical entity. Common brand names based on this INN include Seractil and Dexal, which are primarily focused on the adult patient group.

Regulatory References

  1. EMA referral for ibuprofen and dexibuprofen

What side effects are possible with Dexibuprofen?

Dexibuprofen, a non-steroidal anti-inflammatory drug (NSAID), shares the class-wide risks associated with this category of medication. Official regulatory documents emphasize two primary serious safety concerns: Gastrointestinal Risk and Cardiovascular Risk.

Adverse Reaction Profile

Adverse reactions primarily affect the Gastrointestinal (GI), Nervous, and Immune Systems. Common reactions may include nausea, vomiting, abdominal pain, indigestion, headache, and dizziness. Serious, but less common, reactions documented include:

  • Serious Gastrointestinal Events: Bleeding, ulceration, or perforation of the stomach or intestine, which can be fatal, especially in the elderly. Signs of GI bleeding include vomiting blood or passing black/tarry stools.
  • Serious Cardiovascular Events: An increased risk of arterial thromboembolic events (e.g., heart attack or stroke) is associated with the use of high doses (equipotent to 2400 mg per day of Ibuprofen, or 1200 mg per day of Dexibuprofen) over a prolonged period.
  • Hypersensitivity/Allergic Reactions: Severe reactions, including anaphylactic shock, asthma, and serious skin reactions (e.g., Stevens-Johnson syndrome), may occur.

Safety Restrictions and Contraindications

The use of the lowest effective dose for the shortest possible duration is a required safety note. The drug is contraindicated in patients with a history of allergic reactions to NSAIDs or aspirin, active GI ulcers/bleeding, and for pain relief immediately before or after coronary artery bypass graft (CABG) surgery. Use is not recommended after 20 weeks of pregnancy due to the risk of fetal renal and cardiac issues. Patients with established cardiovascular disease (e.g., uncontrolled high blood pressure, heart failure) or GI disease should use the product only after careful medical consultation and risk assessment.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Dexibuprofen overdose documents specific clinical manifestations and mandates immediate emergency actions. Initial presentations often involve Gastrointestinal System disturbances, such as nausea, vomiting, or abdominal pain, alongside Central Nervous System (CNS) effects, which can include severe headache, confusion, dizziness, and tinnitus.

More severe manifestations documented in regulatory labeling include CNS depression, potentially escalating to seizures or coma, and significant hypotension. Overdose poses a risk for serious end-organ damage, including acute renal failure, metabolic acidosis, and gastrointestinal bleeding or perforation, which are considered life-threatening consequences. Overdose is also explicitly noted in infants and children, with massive ingestions associated with severe outcomes.

Due to the documented risk of severe systemic and organ damage, regulatory authorities mandate that immediate medical attention be sought in all cases of suspected overdose. Individuals must contact emergency services or a national Poison Control Center without delay. Management is officially described as primarily symptomatic and supportive, involving the monitoring of vital signs and renal function, as no specific antidote is known.

Therapeutic Uses of Dexibuprofen

Quick Facts: Uses and Benefits

  • Targets: Pain, discomfort, swelling
  • Conditions: Certain forms of arthritis (osteoarthritis, rheumatoid arthritis), menstrual pain, dental pain
  • Primary Action: Aims to reduce inflammation and relieve associated symptoms

Dexibuprofen is a medicinal agent utilized to manage and alleviate symptoms associated with various conditions that cause pain and inflammation. It is commonly prescribed to provide symptomatic relief from mild to moderate pain levels.

In clinical practice, this medication is an established option for addressing discomfort related to certain inflammatory joint diseases. This includes managing the signs and symptoms of rheumatoid arthritis and osteoarthritis, which are characterized by joint pain, stiffness, and swelling. For patients experiencing painful menstruation (primary dysmenorrhea), Dexibuprofen may also be used to assist in reducing pain.

Furthermore, the drug is indicated for the management of acute pain, such as pain following dental procedures or other minor injuries. It helps in the reduction of inflammation, which can contribute to the relief of symptoms. A healthcare professional can determine if this treatment is appropriate for a patient’s specific condition and discuss the comprehensive safety profile and known indications.

Regulatory References

  1. EMA therapeutic overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Dexibuprofen?

The population eligibility for Dexibuprofen is governed by restrictions in official regulatory labeling, defining groups for whom use is contraindicated, restricted, or not recommended.

Eligibility scope Official Regulatory Statement
Populations for whom use is allowed Adults (18 years and older) who do not possess any of the defined contraindications [EMA SmPC].
Populations for whom use is contraindicated Patients with hypersensitivity to any NSAID (including aspirin) resulting in asthma, rhinitis, or urticaria [EMA SmPC]. Patients with active or recurrent gastrointestinal haemorrhage or peptic ulceration [EMA SmPC]. Patients with severe heart failure (NYHA Class IV), severe renal dysfunction, or severely impaired hepatic function [EMA SmPC]. Women in the third trimester of pregnancy (from the beginning of the sixth month) [EMA SmPC, FDA].
Age-related eligibility rules Use is not recommended in children and adolescents under 18 years for the tablet formulation due to insufficient data [EMA SmPC]. Older adults require special monitoring due to increased risk of adverse reactions [EMA SmPC].
Condition-specific eligibility rules Use requires caution in patients with moderate renal/hepatic impairment and those with uncontrolled hypertension or established cardiovascular disease [EMA SmPC].
Pregnancy and lactation eligibility status Contraindicated during the third trimester of pregnancy [EMA SmPC, FDA]. Not recommended during the first and second trimesters unless clearly necessary [EMA SmPC]. Not recommended during breastfeeding [EMA SmPC].

Connection to the overall eligibility profile:

Official regulatory documents define who can and cannot use Dexibuprofen by establishing clear absolute contraindications for populations with high-risk systemic conditions, such as severe organ failure. Eligibility is also restricted or not recommended for specific age groups and physiological states (e.g., late-stage pregnancy) where safety is not established or risk is unacceptable, according to governmental bodies.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Dexibuprofen primarily through the risk of additive organ toxicity and the alteration of plasma concentrations for co-administered medicines. The following interaction patterns are documented by health authorities.

Pharmacodynamic Interactions and Contraindicated Combinations

Category Regulatory Statement
Other NSAIDs/COX-2 Inhibitors Co-administration is contraindicated due to a documented increased risk of gastrointestinal (GI) ulceration or bleeding.
Anticoagulants/Antiplatelets Concurrent use with drugs like Warfarin or other antiplatelet agents increases the risk of serious bleeding complications.
Low-dose Aspirin Long-term use may reduce the cardioprotective effect of low-dose acetylsalicylic acid. To mitigate this, official guidance advises taking Dexibuprofen at least 8 hours before or 30 minutes after immediate-release aspirin.
Alcohol Consumption presents an additive risk for gastrointestinal bleeding.

Exposure Modification and Risk of Toxicity

Co-administration with Dexibuprofen can officially increase the plasma concentration of several medicines that have a narrow therapeutic index:

  • Lithium and Methotrexate show decreased elimination, leading to an increase in plasma concentration and prolonged half-life.
  • Digoxin serum concentration may be increased.

Additionally, co-administration with Diuretics or Immunosuppressants (e.g., Ciclosporin, Tacrolimus) is documented to increase the risk of nephrotoxicity (kidney damage). Dexibuprofen may also diminish the antihypertensive effect of ACE inhibitors and ARBs. Regulatory documents note that food intake has no clinically significant influence on the extent of Dexibuprofen absorption.

Mechanism of Action

Targeted Inhibition of Cyclooxygenase (COX) Enzymes

Dexibuprofen, the active S(+) enantiomer of ibuprofen, functions as a non-selective, reversible inhibitor of both Cyclooxygenase-1 ( COX-1) and Cyclooxygenase-2 ( COX-2) enzymes. It interacts with the active sites of these enzymes, blocking their ability to convert arachidonic acid into prostanoids. Prostanoids, including PGE2 and PGI2, are key pro-inflammatory, pyretic, and nociceptive mediators.

Modulating Prostanoid-Dependent Signaling Cascades

The inhibition of COX initiates a cascade that influences multiple physiological systems. By suppressing prostanoid formation, the mechanism decreases local vasodilation and the sensitization of peripheral nociceptors (pain-sensing nerves). This attenuates overactive signaling within the pathway and suppresses the elevated hypothalamic thermal set point in the central nervous system.

Resulting Physiological Effects

The mechanism influences biological activity within the COX-prostanoid pathway, which results in characteristic physiological effects. This process limits the impact of excessive prostanoid-mediated activity, leading to attenuated local inflammatory processes and decreased peripheral nociceptor excitability.

Dosage and Administration Information

How to Use Dexibuprofen

Dexibuprofen is an oral medication that is used in accordance with established dosage and scheduling guidelines. The approved administration route for this formulation is oral use via film-coated tablets, typically available in strengths of 200 mg, 300 mg, and 400 mg.

Administration involves providing the medicine in divided doses throughout the day. The usual starting dose for adults is 600 mg per day, which is generally administered in up to three separate single doses. The typical daily dose for maintenance treatment in chronic conditions is between 600 mg and 900 mg. The maximum recommended daily dose for adults is 1200 mg, and a single dose should not exceed 400 mg.

Administration Conditions and Dosing Adjustments

Patients can take dexibuprofen with or without a meal. However, taking the tablet with food is often suggested to help minimize potential gastrointestinal irritation, especially during long-term use. Taking the medication with or after a large meal may result in a delayed onset of action. The score line found on the 200 mg and 400 mg tablets is intended only to facilitate swallowing and should not be used to divide the tablet into equal therapeutic doses.

For most patients, treatment involves using the lowest effective dose for the shortest duration necessary to control symptoms. Specific population groups require dosage modifications: the starting dose is reduced for adults with mild to moderate renal or hepatic impairment. The medication is generally not suitable for children under 8 years of age.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Dexibuprofen

Evidence for Chronic Pain and Inflammation (Osteoarthritis)

The available research for this compound in the context of chronic inflammatory conditions, such as osteoarthritis, includes Randomized Controlled Trials (RCTs) and comparative studies. These studies were applied to examine short-term symptom patterns and assessed outcomes related to daily functioning or activity level, using standardized tools. Studies reported measurements comparing the compound against placebo and other treatments. This evidence helps contextualize reported symptom patterns. The long-term effects are not fully established by high-quality randomized evidence; most extended information comes from post-marketing surveillance reports.

Evidence for Acute Pain Relief (Postoperative Pain and Dysmenorrhea)

For acute conditions like pain after a procedure or menstrual pain (dysmenorrhea), research has focused primarily on short-term clinical trials. These studies monitored outcomes related to physical discomfort over very short observation windows, typically just a few hours post-dose. For acute pain, sample sizes were modest, leading to a classification where certainty remains low. Research explored the onset of the effect for dysmenorrhea, and findings described patterns related to the rapidness of the observed change in discomfort.

Research in Special Populations

Research has explored the compound in the context of fever in children through controlled clinical trials, examining physiological outcomes like the time needed to become fever-free. Findings describe group patterns related to how temperature evolved. Data for certain groups remain insufficient, and long-term effects in the pediatric population are not fully established. Research concerning the compound in older adults has been evaluated, but dedicated studies focusing exclusively on specific outcomes for this group are limited.

Research Gaps and Uncertainties

Key research limitations persist across the evidence base. For acute pain indications, the available sample sizes were modest. Furthermore, long-term effects are not fully established by controlled trials, particularly regarding continuous use for chronic conditions. Comparative evidence is often lacking for certain subgroups or specific outcomes. The research provides context but does not determine whether an individual will respond similarly; the results apply only to the populations studied.

Frequently Asked Questions (FAQ)

Common questions about Dexibuprofen (FAQ)

Q: What is Dexibuprofen used for?

A: Dexibuprofen is an NSAID indicated for the relief of pain and inflammation associated with conditions like osteoarthritis, menstrual pain, or dental pain. Its specific approved uses are determined by the regulatory authority in your region and can be found on the product label.

Q: How does Dexibuprofen differ from Ibuprofen?

A: Dexibuprofen is the pharmacologically active component of Ibuprofen. Ibuprofen is a mixture of two mirror-image molecules (enantiomers), one of which is Dexibuprofen. This means Dexibuprofen may offer similar effects at a lower dose, but the FDA and EMA have specific, separate indications and dosing guidelines for each drug.

Q: Can I stop taking Dexibuprofen once my pain is gone?

A: Generally, NSAIDs like Dexibuprofen are used for short-term relief, and the lowest effective dose should be used for the shortest possible duration. The decision to stop or continue the medication should be based on your specific condition and the directions provided by a healthcare professional.

Q: What are the most common side effects of Dexibuprofen?

A: Like all medicines, Dexibuprofen has potential side effects. Common effects may include gastrointestinal issues such as nausea, indigestion, or abdominal pain. Serious side effects, though less common, can involve the stomach, heart, or kidneys. A complete list of documented side effects is available in the official Patient Information Leaflet.

How should Dexibuprofen be stored and disposed of?

Official Storage and Disposal Instructions

Dexibuprofen must be stored under specific conditions to maintain its quality, as defined in the official regulatory labeling.

Storage Classification Requirement as per Regulatory Labeling
Temperature Requirement Store below 25^circC (77°F).
Packaging Store in the original container or packaging.
Child Safety Keep out of the sight and reach of children.

No special requirements for light or moisture protection are explicitly stated beyond the standard storage temperature. The stated shelf life is established under these specified conditions.

For disposal, official instructions mandate that unused or expired Dexibuprofen must be discarded in accordance with local requirements. The medication is documented as presenting a risk to the environment, and regulatory guidance requires that it not be thrown away via wastewater or household waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Dexibuprofen found in:

A-Z Index: